CDMO vs. CVAC, INO, GTHX, RIGL, NGM, INVA, VIR, INNV, OFIX, and LFMD
Should you be buying Avid Bioservices stock or one of its competitors? The main competitors of Avid Bioservices include CureVac (CVAC), Inovio Pharmaceuticals (INO), G1 Therapeutics (GTHX), Rigel Pharmaceuticals (RIGL), NGM Biopharmaceuticals (NGM), Innoviva (INVA), Vir Biotechnology (VIR), InnovAge (INNV), Orthofix Medical (OFIX), and LifeMD (LFMD). These companies are all part of the "medical" sector.
CureVac (NASDAQ:CVAC) and Avid Bioservices (NASDAQ:CDMO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, community ranking, institutional ownership, dividends, risk, profitability, media sentiment and valuation.
Avid Bioservices has a net margin of -13.10% compared to Avid Bioservices' net margin of -483.85%. CureVac's return on equity of -8.78% beat Avid Bioservices' return on equity.
In the previous week, Avid Bioservices had 6 more articles in the media than CureVac. MarketBeat recorded 8 mentions for Avid Bioservices and 2 mentions for CureVac. CureVac's average media sentiment score of -0.16 beat Avid Bioservices' score of -0.31 indicating that Avid Bioservices is being referred to more favorably in the news media.
CureVac has a beta of 2.51, meaning that its stock price is 151% more volatile than the S&P 500. Comparatively, Avid Bioservices has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500.
Avid Bioservices has higher revenue and earnings than CureVac.
CureVac presently has a consensus price target of $8.33, suggesting a potential upside of 179.64%. Avid Bioservices has a consensus price target of $14.50, suggesting a potential upside of 78.13%. Given Avid Bioservices' higher possible upside, equities analysts plainly believe CureVac is more favorable than Avid Bioservices.
Avid Bioservices received 345 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 66.49% of users gave Avid Bioservices an outperform vote while only 51.16% of users gave CureVac an outperform vote.
17.3% of CureVac shares are held by institutional investors. Comparatively, 97.2% of Avid Bioservices shares are held by institutional investors. 2.4% of Avid Bioservices shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Avid Bioservices beats CureVac on 13 of the 16 factors compared between the two stocks.
Get Avid Bioservices News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDMO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avid Bioservices Competitors List
Related Companies and Tools
